// App-Quantinova.ai

699 : Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution to immune-mediated inflammatory skin response

Researchers

Presenter

  • A. Maroof

Principal Investigators

  • T. Smallie

  • S. Archer

  • C. Simpson

  • M. Griffiths

  • D. Baeten

  • S. Shaw

Medical Centers

  • UCB, Amsterdam, Noord-Holland, Netherlands

  • UCB, Slough, United Kingdom

Locations

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Psoriasis

Biomarkers

  • C-X-C Motif Chemokine Ligand 2

  • Chemokine (C-X-C motif) ligand 1

  • Interleukin 17A

  • Interleukin 6

  • Interleukin-8

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved